Achromobacter xylosoxidans bacteremia in patients with hematologic malignancies
Hernández, J.A.; Martino, R.; Pericas, R.; Sureda, A.; Brunet, S.; Domingo-Albós, A.
Haematologica 83(3): 284-285
1998
ISSN/ISBN: 0390-6078 PMID: 9573685 Document Number: 489470
We report nine cases of Achromobacter xylosoxidans bacteremia diagnosed in patients with hematologic malignancies. There was not an obvious epidemiologic link between cases and the organism was not isolated from any source. Outcome was cure in all nine cases. In our experience, catheter removal is generally required for eradication of A. xylosoxidans.
Document emailed within 1 workday
Related Documents
Mandrell, T.D. 1991: Achromobacter xylosoxidans infection in baboons Laboratory Animal Science 41(5): 506-508Usui, N. 2019: Hematologic Malignancies/Pediatric Malignancies Current Guidelines of Clinical Management and Drug Therapy for Hematological Malignancies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(5): 859-861
Murakami, H.; Saitoh, T.; Kasamatsu, T. 2016: Hematologic Malignancies/Pediatric Malignancies. III. Treatment of Relapsed/Refractory Multiple Myeloma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(5): 539-544
Usui, N. 2017: Hematologic Malignancies/Pediatric Malignancies Acute Leukemia - Current Treatment and Future Perspective Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(5): 378-379
Usui, N. 2011: Hematologic malignancies/ pediatric malignancies-chronic myeloid leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(5): 744
deMagalhaes-Silverman, M.; Bloom, E.J.; Donnenberg, A.; Lister, J.; Pincus, S.; Rybka, W.B.; Ball, E.D. 1996: Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies Bone Marrow Transplantation 17(3): 329-333
Nenova, I.S.; Goranov, S.E.; Mateva, N.G.; Ananoshtev, N.H. 2003: Treatment with fluorated quinolones of febrile neutropenia in patients with hematologic malignancies Folia Medica 45(1): 13-19
Lorgeot, V.; Praloran, V.; Turlure, P.; Denizot, Y. 1997: Concentrations of serum leukemia inhibitory factor (LIF) in patients with hematologic malignancies Leukemia 11(2): 311-312
Niscola, P.; de Fabritiis, P.; Cartoni, C.; Romani, C.; Sorrentino, F.; Dentamaro, T.; Piccioni, D.; Scaramucci, L.; Giovannini, M.; Amadori, S.; Mandelli, F. 2006: Home care management of patients affected by hematologic malignancies: a review Haematologica 91(11): 1523-1529
Pagano, L.; Caira, M.; Candoni, A.; Offidani, M.; Fianchi, L.; Martino, B.; Pastore, D.; Picardi, M.; Bonini, A.; Chierichini, A.; Fanci, R.; Caramatti, C.; Invernizzi, R.; Mattei, D.; Mitra, M.Enza.; Melillo, L.; Aversa, F.; Van Lint, M.Teresa.; Falcucci, P.; Valentini, C.Giovanna.; Girmenia, C.; Nosari, A. 2006: The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study Haematologica 91(8): 1068-1075
Madhavan, T. 1984: Bacterial infections in the compromised host with special emphasis on patients with hematologic malignancies Comprehensive Therapy 10(1): 19-24
Shimazaki, C.; Inaba, T.; Murakami, S.; Oku, N.; Itoh, K.; Ura, Y.; Nakagawa, M.; Fujita, N. 1990: Effect of combination therapy with carumonam and clindamycin on severe infections in patients with hematologic malignancies Japanese Journal of Antibiotics 43(8): 1402-1406
Usui, N. 2009: Hematologic malignancies/pediatric malignancies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(5): 742-743
Pagano, L.; Girmenia, C.; Mele, L.; Ricci, P.; Tosti, M.E.; Nosari, A.; Buelli, M.; Picardi, M.; Allione, B.; Corvatta, L.; D'Antonio, D.; Montillo, M.; Melillo, L.; Chierichini, A.; Cenacchi, A.; Tonso, A.; Cudillo, L.; Candoni, A.; Savignano, C.; Bonini, A.; Martino, P.; Del Favero, A. 2001: Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program Haematologica 86(8): 862-870
Yu, Z.-p.; Ding, J.-h.; Chen, B.-a.; Wu, F.; Gao, C.; Sun, Y.-y.; Chen, J.; Zhao, G.; Wang, J.; Li, Y.-f.; Ding, B.-h.; Qian, J. 2011: Analysis of risk factors for relapse of 82 patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation Zhonghua Zhong Liu Za Zhi 33(4): 283-286
Wu, D.P.; Milpied, N.; Moreau, P.; Mechinaud-Lacroix, F.; Mahe, B.; Le Tortorec, S.; Rapp, M.J.; Bourdin, S.; Mahe, J.M.; Harousseau, J.L. 1994: Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies Bone Marrow Transplantation 14(5): 751-757
Sampi, K. 1987: Cancer chemotherapy combined with a calcium antagonist in patients with hematologic malignancies and solid tumors resistant to standard chemotherapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(3 Part 2): 951-955
Nara, N. 2002: Molecular diagnosis in hematologic malignancies Rinsho Byori. Japanese Journal of Clinical Pathology 50(4): 331-336
Baltz, J.K.; Montello, M.J. 1993: Cladribine for the treatment of hematologic malignancies Clinical Pharmacy 12(11): 805
Wierda, W.G.; Kipps, T.J. 2000: Gene therapy of hematologic malignancies Seminars in Oncology 27(5): 502-511